Charles River Laboratories Demonstrates Expertise in CRISPR/Cas9 Genome Engineering Technology
December 01 2016 - 8:00AM
Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL) today
launched a full, end-to-end service offering of CRISPR/Cas9 genome
engineering technology. Through a licensing arrangement with the
Broad Institute of MIT and Harvard, Charles River can now offer
custom in vivo and in vitro genome editing. With this technology,
Charles River will be able to develop more translational research
models that will ultimately improve the efficiency and
effectiveness of the drug discovery process.
“Utilizing the CRISPR/Cas9 platform, Charles River clients can
work with a single provider for both the in vivo and in vitro
phases of their research,” said Dr. Iva Morse, Corporate Vice
President, Chief Scientific Officer, Global Research Models and
Services. “Working with us, clients can generate custom cell lines
for early, exploratory discovery research, as well as generate in
vivo pharmacology models, produce those models, and then use our
Discovery Services offering to place those models in in vivo
studies.”
Charles River has developed partnerships with three key groups
globally for in vivo model creation services. In North America, the
Company is partnering with Mirimus, a leader in RNA interference
technology specializing in the creation of customized genetically
engineered mouse models. In Japan, Charles River is partnering with
the Laboratory Animal Resource Center, University of Tsukuba, one
of the country’s largest production institutes for genetically
modified mice. In Europe, the Company is aligned with Phenomin ICS,
formerly the Institut Clinique de la Souris, a leader in mouse and
rat creation and phenotyping and a key player in different
strategic phenogenomics efforts, like the International Mouse
Phenotyping Consortium.
In addition to building a network of partners, Charles River has
also prepared a number of academic presentations that showcase
their CRISPR/Cas9 expertise, including:
- A poster entitled Comparative
Analysis of NHEJ and HDR Repair Pathways for Genomic Editing Using
CRISPR/Cas9 Technology in ES Cells was presented at the CRISPR
Genome Editing: From High-throughput Screening to Disease Models
Conference in Copenhagen.
- A second poster, C57BL/6NCrl mouse
models generated by CRISPR/Cas9-mediated gene-editing, was
presented at the CRISPR Precision Genome Editing Congress Europe
2016.
- David Fischer, Executive Director of
Biology and DMPK spoke at the World Preclinical Congress Europe
meeting. Dr. Fischer’s presentation on Vertical Integration of
CRISPR/Cas9 Genome Engineering in Drug Discovery detailed the
numerous applications of CRISPR/Cas9 throughout the drug discovery
process by exploring examples from Charles River case studies.
- Don Liu, Senior Scientist in Charles
River’s Genetically Engineered Models and Services group, will
speak at CRISPR Summit USA. Dr. Liu’s presentation, Efficient
Screening of Mutations Generated by CRISPR/Cas9 Genome Editing,
will touch on the limitations of current post-CRISPR screening
methods and present a sensitive platform for screening
CRISPR-generated mutations for in vitro and in vivo models.
To learn more about Charles River’s strategic CRISPR/Cas9
initiatives, please visit our website.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161201005669/en/
Charles River Laboratories International, Inc.Media Contact:Amy
Cianciaruso, 781-222-6168Corporate Vice President, Public
Relationsamy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2023 to Apr 2024